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ABSTRACT Systemic lupus erythematosus (SLE) is the prototypical systemic autoimmune disease in humans and is characterized
by the presence of hyperactive immune cells and aberrant antibody responses to nuclear and cytoplasmic antigens, including
characteristic anti– double-stranded DNA antibodies. We performed a cross-sectional study in order to determine if an SLE-
associated gut dysbiosis exists in patients without active disease. A group of 20 SLE patients in remission, for which there was
strict inclusion and exclusion criteria, was recruited, and we used an optimized Ion Torrent 16S rRNA gene-based analysis pro-
tocol to decipher the fecal microbial profiles of these patients and compare them with those of 20 age- and sex-matched healthy
control subjects. We found diversity to be comparable based on Shannon’s index. However, we saw a significantly lower Firmic-
utes/Bacteroidetes ratio in SLE individuals (median ratio, 1.97) than in healthy subjects (median ratio, 4.86; P< 0.002). A lower
Firmicutes/Bacteroidetes ratio in SLE individuals was corroborated by quantitative PCR analysis. Notably, a decrease of some
Firmicutes families was also detected. This dysbiosis is reflected, based on in silico functional inference, in an overrepresentation
of oxidative phosphorylation and glycan utilization pathways in SLE patient microbiota.
IMPORTANCE Growing evidence suggests that the gut microbiota might impact symptoms and progression of some autoimmune
diseases. However, how and why this microbial community influences SLE remains to be elucidated. This is the first report de-
scribing an SLE-associated intestinal dysbiosis, and it contributes to the understanding of the interplay between the intestinal
microbiota and the host in autoimmune disorders.
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Metagenomic studies on gut microbiota burst onto the scien-tific scene during the last decade, due to the advent of next-
generation sequencing techniques. In a very short period of time,
microbiologists moved from the study of single, isolated, cultiva-
ble microorganisms, specifically, those able to grow under stan-
dard laboratory conditions, to the investigation of very complex
microbial communities, mainly composed of uncultivable bacte-
ria (1, 2). The first metagenomics reports enabled an overview of
the complexity of our gut microbial communities (3, 4). Further
studies focused on establishing the correlation between the hu-
man gut microbiome, the collective genomes of all microbes in-
habiting the gut (5), and different physiological states, including
those having an influence on health. Currently, we know that the
gut microbiota might affect food and drug metabolism (6), influ-
ences human behavior (7), shifts during the course of pregnancy
(8), displays age-associated changes (9–12), and possesses distinc-
tive features depending on geographical location (12, 13), among
other features. It is also becoming clear that there is a strong link
between dietary patterns and the gut microbial profile (14, 15).
Furthermore, some links have been established between some dis-
orders (for example, obesity and metabolic syndrome) and an
imbalance in the gut microbial ecology, also called dysbiosis (16–
18). Remarkably, intestinal dysbiosis has also been associatedwith
autoimmune diseases, such as rheumatoid arthritis, type 1 diabe-
tes, and inflammatory bowel disease (IBD) (19–21).
Systemic lupus erythematous (SLE) is a prototypical autoim-
mune disease in humans that is characterized by the presence of
hyperactive immune cells and aberrant antibody responses to nu-
clear and cytoplasmic antigens. Genetic, immunological, hor-
monal, and environmental factors contribute to disease suscepti-
bility (22), and its prevalence varies greatly depending on the
population under study, although a prevalence of 2 to 5 cases per
10,000 inhabitants is reportedly considered normal (23). Among
the environmental factors, growing evidence suggests that molec-
ular mimicry as a result of viral infection may contribute to the
development of lupus (24). Also, some reports have highlighted
intestinal infections that may ameliorate SLE symptoms (25), and
a marked difference in the specificity of antibodies to bacterial
DNA in healthy people and SLE patients has been indicated (26).
In fact, there is early evidence of a different abundance of cultiva-
ble intestinal bacteria in SLE (27). Remarkably, it has been sug-
gested that novel SLE biomarkers can be potentially found in the
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humanmicrobiota (28). However, a study of the potential dysbio-
sis associated with SLE had not been tackled until now. Therefore,
in this report we took advantage of next-generation sequencing
techniques to explore the potential interplay of the humanmicro-
biome and SLE. We have proven, for the first time, that there is a
gut microbial dysbiosis associated with SLE.
RESULTS AND DISCUSSION
Despite all the scientific knowledge generated in the last few years,
and although few studies published so far support the dysbiosis
theory as a key factor promoting chronic inflammation in auto-
immune diseases (29–32), there is no scientific work that has
taken advantage of next-generation sequencing techniques to ex-
plore the potential interplay of the human microbiome and SLE,
the prototypical autoimmune disease in humans. Therefore, we
designed our work with the aim of answering if there is an SLE-
associated intestinal dysbiosis and, if so, which microbial popula-
tion groups are related to the dysbiosis.
We defined the SLE population group by considering that
there is a census of about 300 SLE patients in Asturias (from a total
population of about 1,000,000 inhabitants). Thus, we were able to
obtain a group of SLE patients from a well-defined geographical
location to compare themwith a similar group of healthy controls
(HC), considering factors such as sex, age, medication (absence of
antibiotic, steroid, and immunological treatments during the last
6 months), medical history (presenting a wide variety of clinical
SLE manifestations), duration of the disease (2 to 24 years), and
absence of flares of disease activity at the time of sampling (sys-
temic lupus erythematosus disease activity index [SLEDAI] score
of8 at the time of sample collection). The group of SLE patients
included individuals with a large variety of symptoms (Table 1),
allowing us to establish correlations between themicrobial profile
and SLE, which are very likely independent of a specific pattern of
symptoms. This variability in the phenotype of the disease is an
intrinsic characteristic of SLE (22). We also selected patients with
no active disease at the time of sampling, because the clinicalman-
ifestations of the disease in this population group are not biased by
the pharmacological treatment necessary to treat SLE individuals
during disease relapse. Furthermore, mean dietary intakes of en-
ergy, macronutrients, micronutrients, fiber, and phyto-
compounds were recorded, both from patients with SLE and
healthy subjects, and we found that there was no significant dif-
ference between the 2 groups (Table 2). Also, no significant dif-
ference was found between the 2 groups regarding lifestyle-related
factors (smoking, alcohol consumption, physical activity, and use
of vitamin and mineral supplements [data not shown]). This re-
duced the possibility that our analysis was affected by factors
shown to have an influence on the gut microbial profile, such as
age (9), diet (15), or phenolic compound intake (33, 34).
Our work is based on 16S rRNA gene-based data for fecal mi-
crobiota and the bioinformatic analysis of the results. In a previ-
ous work (35), we optimized protocols to study the human fecal
microbial population by using an Ion Torrent PGM sequencing
platform. This methodology was applied in the current study, and
we obtained an average of 592,305 high-quality reads per fecal
sample (see Table S1 in the supplemental material). Rarefaction
curves obtained by plotting the Shannon, Chao1, and phyloge-
netic diversity indexes against the number of sequences (see
Fig. S1 in the supplemental material) showed that a large part of
the diversity of the samples was detected. The microbiota compo-
sition at the phylum and family levels was obtained (Fig. 1; see also
Fig. S2 in the supplemental material). Remarkably, even consid-
ering the broad heterogeneity of the clinical manifestations of SLE
TABLE 1 Demographic, clinical, and immunological features of SLE patients
Subject
no.
Age
(yrs)
Disease
duration
(yrs)
Anti-dsDNA
titer (U/ml)a
Complement C3
(g/liter)a
Complement C4
(g/liter)a Clinical and immunological featuresb
SLE1 43 2 0.3 0.93 0.2 MR, PH, HD, ANA
SLE2 68 3 0.7 0.96 0.18 MR, DL, PH, AR
SLE4 35 4 7.7 1.53 0.22 PH, OU, RD, ANA
SLE5 50 5 18 1.67 0.44 PH, OU, HD, ANA, anti-SSa
SLE6 35 3 48 0.81 0.13 MR, OU, AR, HD, ANA, anti-dsDNA, anti-SSa
SLE7 70 3 27 1.74 0.37 PH, OU, HD, ANA, anti-dsDNA
SLE11 54 24 99.1 1.43 0.28 MR, DL, PH, AR, HD, ANA, anti-dsDNA, anti-Sm
SLE12 58 6 13 0.84 0.22 DL, PH, AR, HD, ANA, anti-SSa, RF
SLE13 40 6 0.6 0.83 0.25 MR, OU, ANA
SLE14 40 12 4 0.92 0.18 AR, SE, RD, ANA, anti-SSb
SLE15 51 24 104 0.83 0.14 MR, DL, PH, AR, SE, HD, ANA, anti-dsDNA, anti-SSa,
anti-SSb, anti-Sm, anti-RNP, anti-CLP
SLE16 54 24 45 1.76 0.3 PH, AR, ANA, anti-dsDNA, anti-SSa
SLE17 46 13 19 0.8 0.11 MR, DL, PH, OU, AR, ANA, anti-dsDNA, anti-SSa, RF
SLE18 43 12 4.1 1.04 0.16 DL, PH, OU, AR, SE, HD, ANA, anti-SSa, RF
SLE19 34 4 0 1.19 0.25 MR, PH, OU, ANA
SLE20 51 7 5.8 0.67 0.14 PH, OU, ANA, anti-SSa
SLE21 59 11 1.2 1.16 0.17 PH, ANA, anti-dsDNA, anti-SSa, anti-CLP
SLE22 64 11 4.4 1.17 0.25 MR, PH, AR, ANA, anti-dsDNA, anti-SSa
SLE24 46 14 0.4 1.08 0.4 MR, PH, HD, ANA, anti-SSa, RF
SLE26 46 20 38 0.89 0.18 MR, PH, OU, RD, HD, ANA, anti-dsDNA.
a At the time of sampling.
b Cumulatively registered. Abbreviations: ANA, antinuclear antibodies; anti-RNP, antiribonucleoprotein antibodies; anti-Sm, anti-Smith antigen antibodies; anti-CLP,
anticardiolipin antibodies; RF, rheumatoid factor; AR, arthritis; DL, discoid lesions; HD, hematological disorder; MR, malar rash; OU, oral ulcers; PH, photosensitivity; RD, renal
disorder; SE, serositis.
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in the individuals under study (Table 1), we obtained a particular
type of microbiota for the SLE group. In this regard, the presence
of anti–double-stranded DNA (dsDNA) antibodies and other
clinical data were organized in a metadata file for all the microbi-
ota profiles. A principal component analysis (PCoA) was per-
formed with both metadata/microbiota profiles, using the vari-
ability of the 16S rRNA gene profiling at different taxonomic
levels. Sample classification according to themetadata revealed no
specific clustering of the samples or correlations with the different
clinical features or anti-dsDNA antibodies (data not shown).
In silico analysis of the sequences highlighted the key findings
of ourwork. A high-quality filtering approachwas used in order to
process the Ion Torrent-generated sequencing data (see Table S1
in the supplemental material); a total of 293,436 unfiltered oper-
ational taxonomic units (OTUs) were identified by using uclust
for de novo OTU picking. Based on each of five alpha-diversity
measures (Chao1, PD whole tree, observed species, Shannon, and
Simpson indexes), patients and controls were not significantly
different (data not shown). Notably, one of the main results was
the identification of a clear dysbiosis between the two study
groups which was characterized by a higher relative abundance of
TABLE 2 General characteristics and mean dietary intake of energy,
macronutrients, fiber forms, and phyto-compounds in patients with
SLE and healthy controls
Characteristic
SLE patients
(n 20)
Healthy controls
(n 20)
Female sex (%) 100 100
Age (yrs) 49.2 10.7b 46.9 8.6
BMI (kg/m2) 26.1 5.3 25.2 4.2
Energy (kcal/day) 2,173.1 722.4 1,875.9 332.8
Lipid (g/day)a 84.5 41.0 85.4 20.5
MUFA (g/day)a 35.3 19.7 35.7 7.6
PUFA (g/day)a 17.2 9.7 17.5 9.4
SFA (g/day)a 24.9 14.1 25.0 6.0
Protein (g/day)a 104.9 27.6 100.6 20.9
Carbohydrates (g/day)a 205.0 75.6 203.5 47.0
Dietary fiber (g/day)a 24.9 10.4 25.3 9.1
Insoluble fiber (g/day)a 16.0 8.6 16.6 7.5
Soluble fiber (g/day)a 2.9 1.5 2.8 1.1
Total isoflavones (mg/day)a 2.4 2.4 2.5 2.7
Total phenolics (mg/day)a 833.2 527.3 916.3 437.8
a Model was adjusted for energy and BMI. PUFA, polyunsaturated fatty acids; MUFA,
monounsaturated fatty acids; SFA, saturated fatty acids.
b Values are means SD.
FIG 1 Aggregate microbiota composition in fecal samples from control (HC) and lupus-affected (SLE) subjects at the phylum level (a) and family level (b). In
panel b, only taxonomic groups representing0.5% are shown.
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Bacteroidetes in the SLE group. Overall, we detected a significant
decrease in the Firmicutes/Bacteroidetes ratio in SLE individuals:
the microbiota of SLE patients, compared with controls, had an
almost-2.5-fold-decreased ratio (Fig. 2A) (P 0.002). Looking at
the different individuals, a gradient from lower (SLE) to higher
(HC) Firmicutes/Bacteroidetes ratios was observed (Fig. 2B). These
16S rRNA gene-based analyses were corroborated by quantitative
PCR (qPCR) analysis. The levels (reported as the log cells/g, with
the interquartile range [IQR] in parentheses) of total fecal bacteria
were 10.62 (9.46 to 10.80) in SLE patients and 10.35 (10.07 to
10.59) in controls. Firmicutes levels in the SLE and control groups
reached 9.69 (8.86 to 10.38) and 9.99 (9.68 to 10.31), respectively,
while those of Bacteroidetes were 10.52 (9.56 to 10.83) and 9.89
(9.59 to 10.23), respectively. No statistically significant differences
in these levels of microbial groups were found between SLE pa-
tients and controls. However, when the data were expressed as the
relative percentages of Firmicutes and Bacteroideteswith respect to
the total bacterial level, a significantly higher (P 0.05) percent-
age of Bacteroidetes was observed in the SLE group. Moreover,
when the Firmicutes/Bacteroidetes ratio was calculated, a statisti-
cally significant (P 0.01) decrease in the SLE group with respect
to the control group was found (0.94 [0.90 to 0.98] versus 1.01
[0.96 to 1.06], respectively). The differences in the ratios based on
qPCR were less pronounced than the differences obtained with
the 16S rRNA profiling, likely because the two techniques provide
different kinds of information: a relative proportion of sequences
(from the 16S rRNA gene-based analysis) versus an absolute
quantification of sequences (via qPCR). Thus, the fact that we
obtained clear evidence for a significantly lower Firmicutes/Bacte-
roidetes ratio in SLE patients when we used two different culture-
independent techniques supports the soundness and reliability of
our analyses. The phyla Bacteroidetes and Firmicutes include the
most abundant components of the human gut microbiota (36).
Dysbiosis between Firmicutes and Bacteroidetes in the human gut
has been described in previous studies in association with some
disorders. The ratio between Firmicutes and Bacteroidetes de-
creases in human type 2 diabetes compared with controls (37).
Also, most studies of the microbiota in people with Crohn’s dis-
ease report a decrease in the abundance of Firmicutes and an in-
crease in Bacteroidetes in association with the disease (38). An
FIG 2 (A) Box plot of Firmicutes/Bacteroidetes ratios (median IQR) in SLE patients versus healthy controls. (B) Percentages of 16S rRNA reads ofBacteroidetes
(red bars) and Firmicutes (blue bars) in the DNA extracted from fecal samples of SLE patients (SLE codes) and healthy controls (HC codes). Ratios are
significantly different (P 0.002).
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opposite situation is observed in obesity, in which the dysbiosis is
characterized by an increase in the Firmicutes/Bacteroidetes ratio
(17). Therefore, this specific microbial balance between the more
abundant phyla in the human gut seems to be dependent on the
physiology of the disorder. In relation to this, it has been reported
that this equilibrium is susceptible to modification by shifts in the
dietary pattern. Wu et al. (15) reported that Firmicutes levels were
positively associated with a low-fat/high-fiber diet. Also, dietary
interventions, including whole grain in the diet, increase the Fir-
micutes/Bacteroidetes ratio (39).
We prepared scatter plots (see Fig. S3A in the supplemental
material), and they clearly highlighted a positive association be-
tween Firmicutes in healthy controls (P 0.01) and Bacteroidetes
in SLE patients (P  0.001). This association was confirmed at
lower taxonomic levels, and normalized abundances of the classes
Bacteroidia (phylum Bacteroidetes) and Clostridia (phylum Firmi-
cutes) and the orders Bacteroidales and Clostridiales differed sig-
nificantly between the SLE patients and the healthy controls (see
Fig. S3B). At the family level, Lachnospiraceae (P  0.05) and
Ruminococcaceae (P  0.05) were positively associated with
healthy controls (see Fig. S4 and S5 and Table S2 in the supple-
mental material).
Statistical differences between the two groups (HC and SLE)
were calculated by a PERMANOVA test, with the distance data
obtained after ordination analysis (PCoA) using PAST v 3.1 (40).
In all cases, data from the relative taxa abundances were used, and
distances were computed according to the Bray-Curtis similarity
index. The groups of SLE and HC differed statistically whenever
phylum- or family-level data were used (P  0.01 or P  0.02,
respectively).
Unsupervised PCoA of the 16S rRNA sequence data identified
the phyla Bacteroidetes and Firmicutes as the main gradients for
SLE and healthy control groups, respectively (Fig. 3A). PCoA at
the family level showed that the families Lachnospiraceae and Ru-
minococcaceae were located near the healthy controls (Fig. 3B).
Interestingly, Lachnospiraceae was the most abundant family in
the feces of both study groups (Fig. 1; see also Fig. S2 in the sup-
plemental material). Depletion of Lachnospiraceae and Rumino-
coccaceae has been associated with Clostridium difficile infections
and nosocomial diarrhea (41). Also, several studies showed a de-
crease of Lachnospiraceae in IBD patients, and this family has been
suggested as a biomarker of disease activity (42–44). However, the
functional consequences of the depletion of these bacteria in the
previously mentioned intestinal diseases remain to be investi-
gated. Although the amplicons of the 16S rRNA sequences could
be relatively short to perform a totally reliable population struc-
ture analysis at the genus/species level, it is noteworthy that the
relative abundance of sequences assigned to Bacteroides spp. were
significantly higher in SLE samples (P  0.02). In the control
group, we also found a significantly higher (P  0.05) relative
abundance of sequences tentatively assigned to Desulfovibrio, the
most common genus of sulfate-reducing bacteria in the human
gut (45). It is worthmentioning that some authors have described
how dysbiosis could affect mucosal barrier function and impair
immunoregulatorymechanisms, leading to pathological effects in
systemic immunity. Using animalmodels, a direct involvement of
components of the microbiota in chronic intestinal inflammation
(46) and the protective role of specific commensals in avoiding
bacterial translocation (47) have been demonstrated. Finally, we
should bear in mind that nonsteroidal anti-inflammatory drugs
and the antimalarial treatment of SLE patients could have an in-
fluence on the observed dysbiosis.
In our study, we also determined the tentative metagenomes
from phylogenetically associated reference genomes. Our aimwas
to highlightmetabolic pathways and shifts associatedwith the SLE
population comparedwith controls.We inferred the functionality
of the different putative metagenomes by using PICRUSt soft-
ware, which allows the prediction of metabolic pathways from the
16S rRNA reads (48). A functional analysis using the data ob-
tained from the KEGG pathways at level 3 allowed us to detect
certain processes potentially associated with either healthy con-
trols or SLE. KEGG levels are the different hierarchical subdivi-
sions in which the functions of a biological system (cell, organism,
or ecosystem) are arranged according to information organized in
the KEGG database (http://www.genome.jp/kegg/kegg1a.html).
Pathways displaying a difference in mean proportions between
healthy controls and SLE groups of at least 0.1% are represented in
Fig. S6 in the supplemental material. Some glycan degradation
pathways are slightly overrepresented in the microbiota of SLE
patients, probably due to the higher abundance of Bacteroidetes in
these samples.Bacteroidetes, and specifically themain genus of this
phylum, Bacteroides, have been shown to display broad glycan-
degrading abilities (49). The same occurs with lipopolysaccharide
biosynthesis proteins, which is in direct relation to the higher
abundance of Bacteroidetes in the SLE samples. Remarkably, oxi-
dative phosphorylation processes seem to be associated with SLE
patients. This finding indicates that some bacteria able to perform
oxidative phosphorylation may be better adapted to the intestinal
ecosystem of individuals with SLE, and this could be related to the
imbalance in the oxidative stress environment at the intestinal
level that has been linked to some autoimmune diseases (48).
In summary, understanding and potentially manipulating im-
mune responses through the action of intestinal microbiota com-
prise one of the most active fields in probiotic and prebiotic re-
search. Most likely, the dysbiosis defined in this work is the
consequence of the altered immune function of SLE patients. At
present, the treatment of SLE patients is exclusively performed
with drugs, and our findings could indicate that challenging the
immune system with the bacteria depleted in SLE, or substances
promoting their growth, could influence SLE physiology. To the
best of our knowledge, experimental papers about the relationship
of the human gut microbiome and SLE have not been published,
and this is the first report describing an SLE-associated intestinal
dysbiosis. Thus, our results establish the basis to delve deeper into
the understanding of the relationship between the human gut mi-
crobiota and autoimmune diseases.
MATERIALS AND METHODS
Ethics statement. Ethics approval for this study (reference code
AGL2010-14952; grant title “Towards a better understanding of gut mi-
crobiota functionality in some immune disorders”) was obtained from
the Bioethics Committee of CSIC (Consejo Superior de Investigaciones
Científicas) and from the Regional Ethics Committee for Clinical Re-
search (Servicio de Salud del Principado de Asturias) in compliance with
the Declaration of Helsinki. All determinations were performedwith fully
informed written consent from all participants involved in the study.
Study subjects. The study sample comprised 20 patients with SLE
(SLE codes) and 20 healthy controls (HC codes). SLE patients were se-
lected from the updated Asturian Register of Lupus (Asociación Lúpicos
de Asturias, Oviedo, Spain). All of them fulfilled at least four of the Amer-
ican College of Rheumatology criteria for SLE (50). The individuals re-
Intestinal Dysbiosis Associated with SLE
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FIG 3 PCoA results for the 16S rRNA profiles at the phylum (A) and family (B) level. The presence or absence of SLE was further included as metadata. HC,
closed circles; SLE, open triangles.
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cruited for the SLE group were in remission and had not had any immu-
notherapy or corticoid treatment during the previousmonths, since those
are the treatments that could have the strongest influence on the physiol-
ogy of the patients. All patients were women of Caucasian origin, 49.2
10.7 years old (mean standard deviation [SD]), and had no active dis-
ease at the time of sampling (SLEDAI score of8). Information on clin-
ical manifestations was obtained by reviewing clinical records (Table 1).
Patients were also asked precise questions regarding treatment received
during the previous 6 months. Only those individuals who had not used
antibiotics, glucocorticoids, immunosuppressive drugs, monoclonal an-
tibodies, or other immunotherapies were recruited for the study. Eighteen
patients were receiving antimalarial treatment, and all of them were reg-
ular consumers of nonsteroidal anti-inflammatory drugs. Twenty age-
matched healthy women (46.9 8.6 years old) from the same population
were recruited as controls.
(i) Nutritional assessment. Variables of macro- and micronutrient
intakes were collected by means of a semiquantitative food frequency
questionnaire that included 160 items. During a personal interview, car-
ried out within 7 days after the collection of the fecal sample, subjects were
asked item by itemwhether they usually ate the food and, if so, howmuch
they ate. For this purpose, three different serving sizes of each cooked food
were presented in pictures to the participants so that they could choose
from up to 7 serving sizes (from “less than the small one” to “more than
the large one”). For some of the foods consumed, amounts were recorded
in household units, by volume, or by measuring with a ruler. Special
attention was paid to cooking practices and number and amount of in-
gredients used in each recipe, as well as questions concerning menu prep-
aration (e.g., type of oil or milk used).
Food intake was analyzed for energy and macro- and micronutrient
contents by using the nutrient food composition tables developed by
CESNID (51). Total, soluble, and insoluble fiber intake was completed
based on Marlett food composition tables (52), and polyphenol content
was calculated from theU.S.Department of Agriculture (USDA)Nutrient
Database (53).
(ii) Anthropometric measures. The body mass index (BMI) was cal-
culated from the following formula: weight/(height)2 (in kg/m2). Height
was registered by using a stadiometer with an accuracy of1 mm (Año-
Sayol, Barcelona, Spain). Subjects were barefoot, in an upright position,
and with the head positioned in the Frankfort horizontal plane. Weight
was measured on a scale with an accuracy of 100 g (Seca, Hamburg,
Germany).
(iii) Lifestyle-related factors. During the interview, other factors as-
sociated with the lifestyle of the subject were registered. Smoking habit,
physical activity, alcohol consumption, and supplements use were in-
cluded in the questionnaire. Smoking status was categorized as non-
smoker (including exsmokers and occasional smokers) or current
smoker. Those subjects who reported that they never exercised were cat-
egorized as physically inactive. “Regular alcohol consumer” refers to those
subjects whodeclared a regular consumption of alcoholic drinks. Also, the
use of vitamin and mineral supplements during the last month was self-
reported.
Fecal sample collection and DNA extraction. Fresh fecal material
(between 10 and 50 g per person) was collected in a sterile container and
immediately manipulated and homogenized within a maximum of 3 h
from defecation. During the waiting period, from defecation to homoge-
nization, samples were kept at 4°C. Thirty milliliters of RNAlater solution
(Applied Biosystems, Foster City, CA) was added to 10 g of sample, and
the mixture was homogenized in a sterile bag, using a stomacher appara-
tus (IUL Instruments, Barcelona, Spain) with three cycles at high speed,
1 min per cycle. Homogenized samples were then stored at 80°C until
use.
For DNA extraction, samples were thawed and the QIAamp DNA
stool minikit (Qiagen Ltd., Strasse, Germany) was used as previously de-
scribed (35).
16S rRNA gene amplification. Partial 16S rRNA gene sequences were
amplified from extracted DNA by using the primer pair Probio_Uni (5=-
CCTACGGGRSGCAGCAG-3’)/Probio_Rev (5=-ATTACCGCGGCTGC
T-3=) (35), which targets the V3 region of the 16S rRNA gene sequence.
The PCR conditions usedwere 5min at 95°C, 35 cycles of 30 s at 94°C, 30 s
at 55°C, and 90 s at 72°C, followed by 10 min at 72°C. Amplification was
carried out using a Verity thermocycler (Applied Biosystems). The integ-
rity of the PCR amplicons was analyzed by electrophoresis on an Experion
workstation (Bio-Rad, Hertfordshire, United Kingdom).
Ion Torrent PGM sequencing of 16S rRNA gene-based amplicons.
The PCR products derived from amplification of specific 16S rRNA gene
hypervariable regions were purified by electrophoretic separation on a
1.5% agarose gel and the use of a Wizard SV Gen PCR cleanup system
(Promega, Madison, WI), followed by a further purification step involv-
ing Agencourt AMPure XP DNA purification beads (Beckman Coulter
GenomicsGmbH,Bernried,Germany) in order to remove primer dimers.
The DNA concentration of the amplified sequence library was estimated
through use of the Experion system (Bio-Rad). From the concentration
and the average size of each amplicon library, the amount of DNA frag-
ments permicroliter was calculated and libraries for each runwere diluted
to 3E9 DNA molecules prior to clonal amplification. Emulsion PCR was
carried out using the Ion OneTouch 200 template kit v2 DL (Life Tech-
nologies, Guilford, CA) according to the manufacturer’s instructions. Se-
quencing of the amplicon libraries was carried out on 316 chips by using
the Ion Torrent PGM system and employing the Ion Sequencing 200 kit
(Life Technologies) according to the supplier’s instructions at the DNA
sequencing facility, GenProbio s.r.l. After sequencing, the individual se-
quence reads were filtered with the PGM software to remove low-quality
and polyclonal sequences. Sequences matching the PGM 3= adaptor were
also automatically trimmed. All PGM quality-approved, trimmed, and
filtered data were exported as SFF files.
Sequence-based microbiota analysis. The SFF files were processed
using QIIME (54). Quality control retained sequences had lengths be-
tween 150 and 200 bp, a mean sequence quality score of 25, and with
truncation of a sequence at the first base if a low-quality rolling 10-bp
window was found. Presence of homopolymers of 7 bp and sequences
withmismatched primers were omitted. In order to calculate downstream
diversitymeasures (alpha and beta diversity indices, Unifrac analysis), 16S
rRNA OTUs were defined at 97% sequence homology by using uclust
(55). Chimeric sequences were removed using ChimeraSlayer (56). Fur-
thermore, OTUs that included less than 10 sequences were filtered using
QIIME (54). All reads were classified to the lowest possible taxonomic
rank by using QIIME and a reference data set from the Ribosomal Data-
base Project (57). The sequence data features of all the samples are in-
cluded in Table S1 in the supplemental material.
Different alpha diversity indexes were calculated using QIIME and
information from the OTU tables using the alpha_diversity.py script. The
different diversity metrics were set by passing the option –s to the script.
The following indexes were calculated for every sample and compared
between groups by using a two-sided Student’s t test: Chao1, PD whole
tree, observed species, Shannon, and Simpson.
Analysis by qPCR. Quantification of total fecal bacteria, Firmicutes,
and Bacteroidetes by qPCR was performed by using previously described
primers and conditions (58–60). Analyses were done in duplicate in a
7500 Fast real-time PCR system (Applied Biosystems) using Sybr green
PCR master mix (Applied Biosystems). Standard curves were made with
pure cultures, grown under anaerobic conditions at 37°C, of Escherichia
coli LMG 2092 in Gifu anaerobic medium (GAM; Nissui Pharmaceutical
Co., Tokyo, Japan), Faecalibacterium prausnitzii DMSZ 17677 in RCM
formula (Oxoid Ltd., Basingstoke, Hampshire, United Kingdom), and
Bacteroides thetaiotaomicron DSMZ 2079 in GAM.
Functional inference. The functionality of the different metag-
enomes, grouped by disease status (healthy control versus SLE), was pre-
dicted using the software PICRUSt 0.9.1 (http://picrust.github.io), which
has been explained in detail elsewhere (48). In short, this software allows
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the prediction of functional pathways from the 16S rRNA reads. First, a
collection of closed-reference OTUs was obtained from the filtered reads
by usingQIIME v 1.7.0 (54) and by querying the data against the IMG/GG
reference collection (GreenGenes database, May 2013 version; http://
greengenes.lbl.gov). Reverse-strand matching was enabled during the
query, and OTUs were picked at a 97% identity. A BIOM-formatted table
(biological observation matrix [61]) was obtained with the pick_closed_
reference_otus.py script. This table, containing the relative abundances of
the different reference OTUs in all the metagenomes, was normalized
based on the predicted 16S rRNA copy number by using the script
normalize_by_copy_number.py. Final functional predictions, in-
ferred from the metagenomes, were created with the script predict_
metagenomes.py. When necessary, tab-delimited tables were obtained
with the script convert_biom.py.
Analysis of predicted metagenomes. PICRUSt and QIIME provide a
number of scripts that can be useful for analyzing both 16S rRNA gene
relative abundances and the predicted metabolic data. Predicted metag-
enomic contents were collapsed at KEGG pathway level 3 (http://
www.genome.jp/kegg/pathway.html) with the categorize_by_function
.py script, and the data were analyzed statistically by using STAMP v 2.0.0
(62). STAMP allows data filtering and the application of different statis-
tical tests and corrections, including PCoA. It also generates different
graphics, including box plots, error plots, and scatter plots. Data of
the KEGG pathway distributions were plotted by using the script
summarize_taxa_through_plots.py. Associations of different taxonomic
categories to SLE were statistically analyzed with the script otu_category_
significance.py.
Statistical analyses. Statistical analysis was performed using IBM-
SPSS version 19.0 (IBMSPSS, Inc., Chicago, IL). For descriptive purposes,
in Table 2 the mean values are presented as means  SD on untrans-
formed variables. Differences between SLE patients and controls were
compared by using a multivariate linear model, including energy intake
and BMI as covariates.
Individuals were ordered according to their sequence data composi-
tion by principal component analysis using the taxonomic data at the
phylum and family levels. Patterns were extracted using all the variations
from the taxonomic data via an indirect method as a model and SLE as
metadata. To analyze the associations between inferred metabolic path-
ways and SLE, metabolic pathways with very low abundance levels
(0.001 in 50% of the samples) were excluded from all analyses. Associ-
ation of KEGG pathways to SLE were identified by running two-sided
Welch tests on every pair of means. This test is a variation of Student’s
t test and is used when equal variance cannot be assumed in both groups.
Confidence intervals (95%) were obtained by inverting the Welch’s tests.
The false discovery rate (FDR) correction (48, 63) was finally applied in all
cases, and significant differences between healthy controls and SLE pa-
tients were only considered when below a P value of 0.05 or a q value
below 0.2. P and q values at the phylum and family levels are included in
Table S2 in the supplemental material. In the particular case of the family
Desulfovibrionaceae (withP 0.05), further statistical analysis was carried
out for sequences tentatively assigned to the genusDesulfovibirio by using
a one-sided t test.
In relation to qPCR results, not all the bacterial groups showed normal
distribution; therefore, differences in bacterial levels between groups of
individuals were analyzed using a nonparametric test (Mann-Whitney
U test).
Nucleotide sequence accession number. The raw sequences reported
in this article have been deposited in the NCBI Short Read Archive (SRA;
study accession number SRP028162).
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